| Beyond conventional immune-checkpoint inhibition—novel immunotherapies for renal cell carcinoma DA Braun, Z Bakouny, L Hirsch, R Flippot, EM Van Allen, CJ Wu, ... Nature reviews Clinical oncology 18 (4), 199-214, 2021 | 218 | 2021 |
| Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study R Flippot, C Dalban, B Laguerre, D Borchiellini, G Gravis, S Négrier, ... Journal of Clinical Oncology 37 (23), 2008-2016, 2019 | 135 | 2019 |
| Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features BA McGregor, RR McKay, DA Braun, L Werner, K Gray, A Flaifel, ... Journal of Clinical Oncology 38 (1), 63, 2020 | 126 | 2020 |
| Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma E Rassy, R Flippot, L Albiges Therapeutic advances in medical oncology 12, 1758835920907504, 2020 | 118 | 2020 |
| Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: a propensity score matching analysis from … L D’Ambrosio, N Touati, JY Blay, G Grignani, R Flippot, AM Czarnecka, ... Cancer 126 (11), 2637-2647, 2020 | 106 | 2020 |
| Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma Z Bakouny, DA Braun, SA Shukla, W Pan, X Gao, Y Hou, A Flaifel, S Tang, ... Nature communications 12 (1), 808, 2021 | 100 | 2021 |
| Long non-coding RNAs in genitourinary malignancies: a whole new world R Flippot, G Beinse, A Boilève, J Vibert, GG Malouf Nature Reviews Urology 16 (8), 484-504, 2019 | 96 | 2019 |
| Immune checkpoint inhibitors: toward new paradigms in renal cell carcinoma R Flippot, B Escudier, L Albiges Drugs 78, 1443-1457, 2018 | 74 | 2018 |
| Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma S Abou Alaiwi, W Xie, AH Nassar, S Dudani, D Martini, Z Bakouny, ... Journal for ImmunoTherapy of Cancer 8 (1), 2020 | 71 | 2020 |
| Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma L Hirsch, R Flippot, B Escudier, L Albiges Drugs 80, 1169-1181, 2020 | 67 | 2020 |
| Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors S Abou Alaiwi, AH Nassar, W Xie, Z Bakouny, JE Berchuck, DA Braun, ... Cancer immunology research 8 (8), 1075-1084, 2020 | 61 | 2020 |
| Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma L Hirsch, NM Chanza, S Farah, W Xie, R Flippot, DA Braun, N Rathi, ... JAMA oncology 7 (12), 1815-1823, 2021 | 50 | 2021 |
| Non–clear cell renal cell carcinomas: from shadow to light L Albiges, R Flippot, N Rioux-Leclercq, TK Choueiri Journal of Clinical Oncology 36 (36), 3624-3631, 2018 | 48 | 2018 |
| Cancer subtypes classification using long non-coding RNA R Flippot, GG Malouf, X Su, R Mouawad, JP Spano, D Khayat Oncotarget 7 (33), 54082, 2016 | 41 | 2016 |
| On the shoulders of giants: the evolution of renal cell carcinoma treatment—cytokines, targeted therapy, and immunotherapy JP Dutcher, R Flippot, J Fallah, B Escudier American Society of Clinical Oncology Educational Book 40, 418-435, 2020 | 30 | 2020 |
| Characteristics of BRAFV600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients C Fouchardière, R Cohen, D Malka, R Guimbaud, H Bourien, A Lièvre, ... The oncologist 24 (12), e1331-e1340, 2019 | 30 | 2019 |
| Sarcomatoid dedifferentiation in renal cell carcinoma: from novel molecular insights to new clinical opportunities V Debien, J Thouvenin, V Lindner, P Barthélémy, H Lang, R Flippot, ... Cancers 12 (1), 99, 2019 | 29 | 2019 |
| Prognosis of incidental brain metastases in patients with advanced renal cell carcinoma RR Kotecha, R Flippot, T Nortman, A Guida, S Patil, B Escudier, ... Journal of the National Comprehensive Cancer Network 19 (4), 432-438, 2021 | 28 | 2021 |
| Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers GG Malouf, R Flippot, Y Dong, RG Dinatale, YB Chen, X Su, E Compérat, ... Scientific reports 10 (1), 701, 2020 | 27 | 2020 |
| Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma R Flippot, R Mouawad, JP Spano, M Rouprêt, E Compérat, MO Bitker, ... Scientific reports 7 (1), 8540, 2017 | 26 | 2017 |
